CAMK2D
MOLECULAR TARGETcalcium/calmodulin dependent protein kinase II delta
CAMK2D (calcium/calmodulin dependent protein kinase II delta) is targeted by 34 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).
Compounds Targeting CAMK2D
Ranked by bioassay confidence score (PubChem active assay count × evidence quality).
| # | Compound | Confidence | Active Assays |
|---|---|---|---|
| 1 | erlotinib | 5.55 | 256 |
| 2 | tofacitinib | 4.65 | 104 |
| 3 | alvocidib | 4.52 | 91 |
| 4 | ruxolitinib | 4.23 | 68 |
| 5 | palbociclib | 4.22 | 67 |
| 6 | bi 2536 | 4.01 | 54 |
| 7 | midostaurin | 3.85 | 46 |
| 8 | brigatinib | 3.81 | 44 |
| 9 | abemaciclib | 3.66 | 38 |
| 10 | baricitinib | 3.56 | 34 |
| 11 | tae 684 | 3.43 | 30 |
| 12 | fedratinib | 3.40 | 29 |
| 13 | gilteritinib | 3.40 | 29 |
| 14 | ribociclib | 3.26 | 25 |
| 15 | lestaurtinib | 3.04 | 20 |
| 16 | pf 03758309 | 3.00 | 19 |
| 17 | ruboxistaurin | 2.94 | 18 |
| 18 | momelotinib | 2.89 | 17 |
| 19 | r 406 | 2.83 | 16 |
| 20 | k 252a | 2.83 | 16 |
| 21 | ro 316233 | 2.83 | 16 |
| 22 | pha 665752 | 2.71 | 14 |
| 23 | crenolanib | 2.71 | 14 |
| 24 | atuveciclib | 2.56 | 12 |
| 25 | gsk 461364 | 2.40 | 10 |
| 26 | su 014813 | 2.20 | 8 |
| 27 | decernotinib | 2.20 | 8 |
| 28 | enzastaurin | 2.08 | 7 |
| 29 | rg 547 | 2.08 | 7 |
| 30 | asp 3026 | 2.08 | 7 |
| 31 | ucn 01 | 1.79 | 5 |
| 32 | alsterpaullone | 0.69 | 1 |
| 33 | KN 92 [Supplementary Concept] KN 93 isomer; | 0.69 | 1 |
| 34 | sp600125 | 0.69 | 1 |
About CAMK2D as a Drug Target
CAMK2D (calcium/calmodulin dependent protein kinase II delta) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 34 compounds with documented CAMK2D interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.
CAMK2D inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.